Dehydrozingerone is the ginger-derived half of curcumin: a permitted flavor material and a laboratory curiosity for about forty years. Everything claimed for it comes from cells, flies, mice and rats — less weight gain, better sugar handling, healthier inflamed organs, faster wound closure. None of this has been seen in a person. It sits at the earliest stage of evidence. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 75–86 mg/dL | Tracks the main proposed metabolic effect |
| HbA1c | 4.8–5.4% | Integrates glucose control over ~3 months |
| Fasting insulin | 2–5 µIU/mL | Detects insulin resistance before glucose moves |
| hs-CRP | Below 0.5 mg/L | Tracks the anti-inflammatory claim |
| ALT | 10–26 U/L (men), 8–22 U/L (women) | Safety marker for hepatic handling of an untested compound |
| eGFR | Above 90 mL/min/1.73 m² | Confirms renal reserve and excludes the avoid-list threshold |
| Platelet count | 150–400 × 10⁹/L | Establishes the coagulation baseline before an antiplatelet-active compound |
| Platelet function closure time | No established target on this compound; track the change from the individual's own pre-dose baseline | Detects the additive antiplatelet effect that is the most plausible harm |
Cadence: Baseline within two weeks before the first dose; liver enzymes and a complete blood count at week 4; the full panel at week 12 at the end of the trial period; and once more after the 4-week washout.